Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer

Table 3 FcγRIIa and FcγRIIIa biomarkers of the risk of disease progression

			Sensitivity	Specificity	Likelihood ratio		Predictive value
					Positive	Negative	Positive	Negative
Men	No risk
	HH/FF	P < 0.0001	0.00%	80.00%	0.00	1.25	0.00%	40.00%
	RR/VV	P < 0.0001	0.00%	83.33%	0.00	1.20	0.00%	55.56%
	Moderate risk
	HR/FF	P = 0.0005	12.50%	66.67%	0.37	1.31	25.00%	46.15%
	High risk
	HH/VF	P = 0.0002	66.67%	60.00%	1.67	0.56	66.67%	60.00%
	HR/VF	P = 0.004	75.00%	44.44%	1.35	0.56	54.55%	66.67%
	RR/VF	P < 0.0001	100.00%	16.67%	1.20	0.00	44.44%	100.00%
Women	No risk
	HH/VV	P < 0.0001	0.00%	61.54%	0.00	1.62	0.00%	80.00%
	HR/VV	P = 0.004	0.00%	92.31%	0.00	1.08	0.00%	63.16%
	RR/FF	P < 0.0001	0.00%	66.67%	0.00	1.50	0.00%	66.67%
	High risk
	HH/VF	P < 0.0001	100.00%	38.46%	1.62	0.00	20.00%	100.00%
	RR/VF	P < 0.0001	100.00%	33.33%	1.50	0.00	33.33%	100.00%

The statistical data were obtained by using Diagnostic test evaluation/MedCalc-statistical software. Values of P < 0.05 were considered significant.